Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved
Madrigal Pharmaceuticals, Inc. (MDGL) shares fell 0.5% to $531.52 as of September 18, 2026, a slight decline from the prior close of $534.40. BestStocks flagged the session as a major change for MDGL. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MDGL fell 0.5% to $531.52
Madrigal Pharmaceuticals is trading up 2.76% to $548.91, driven by anticipation ahead of the company's presentation at the 2026 Cantor Global Healthcare Conference tomorrow (September 10), according to the web catalyst and corroborated by investor relations announcements cited by Google's AI Overview. The gain reflects typical pre-conference accumulation by institutional investors ahead of updates on Rezdiffra commercialization and pipeline developments. Volume of 191,812 shares at 370 minutes into the session is 0.85x time-adjusted normal, indicating steady participation without spike. Madrigal's presentation at Cantor Global Healthcare Conference on September 10, 2026, followed by Q3 earnings scheduled for November 3, 2026 (consensus EPS estimate: −$0.91).
What it means for Madrigal Pharmaceuticals, Inc. investors
For Madrigal Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. Weighing against that: Material negative event; Negative session, down 0.5%. Wall Street's consensus price target sits at $677.00, implying +27.4% upside from $531.52. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 46 days out, the next report is the most likely near-term test of the move.
MDGL price reaction
MDGL last traded at $531.52, down $2.88 (-0.54%) from the previous close of $534.40. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $511.97 and $546.93, and it currently sits about 56% of the way up that band.
Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)
The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $677.00, 27.4% above the recent $531.52. Over the past 90 days analysts logged 1 upgrade, 2 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.
The bullish case
- Wall Street's consensus price target of $677.00 implies +27.4% upside from $531.52.
- The Street's most bullish target is $962.00 (+81.0%).
- 1 analyst upgrade in the past 90 days, most recently Wolfe Research to Outperform (2026-08-04).
The bearish case
- Material negative event.
- Negative session, down 0.5%.
- Madrigal Pharmaceuticals filed an 8-K material event report today (SEC mdgl-20260730.htm) coinciding with an earnings report, triggering a 14.28% intraday decline to $468.76.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDGL
In-depth MDGL event analyses
Frequently asked questions about MDGL
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?
MDGL fell 0.5% to $531.52. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did MDGL stock fall?
MDGL lost 0.54% ($2.88) versus the prior close of $534.40, last trading at $531.52 on 1.0× average volume.
When is Madrigal Pharmaceuticals, Inc.'s next earnings date?
MDGL's next earnings report is estimated for 2026-11-03 — about 46 days away.
What is the analyst price target for MDGL?
The consensus analyst price target for MDGL is $677.00, about 27.4% above the current $531.52. Over the past 90 days, analysts recorded 1 upgrade, 2 maintains, and 0 downgrades.
How BestStocks tracks MDGL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MDGL-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.